Compare · BIIB vs SOPH
BIIB vs SOPH
Side-by-side comparison of Biogen Inc. (BIIB) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $27.62B, about 72.4x SOPH ($381.3M).
- Over the past year, BIIB is up 51.5% and SOPH is up 70.9% - SOPH leads by 19.5 points.
- SOPH has been more active in the news (48 items in the past 4 weeks vs 14 for BIIB).
- BIIB has more recent analyst coverage (25 ratings vs 13 for SOPH).
- Company
- Biogen Inc.
- SOPHiA GENETICS SA
- Price
- $187.10-1.21%
- $5.23-0.29%
- Market cap
- $27.62B
- $381.3M
- 1M return
- +1.82%
- +2.55%
- 1Y return
- +51.46%
- +70.92%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 14
- 48
- Recent ratings
- 25
- 13
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest BIIB
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
- SEC Form 10-Q filed by Biogen Inc.
- Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Biogen Inc.
- SEC Form DEF 14A filed by Biogen Inc.
- FDA Approval for ZURZUVAE issued to BIOGEN INC
- Biogen upgraded by UBS with a new price target
- Biogen upgraded by Wells Fargo with a new price target
- TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
- Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Latest SOPH
- Chief Medical Officer Menu Philippe sold $24,089 worth of Ordinary Shares (5,000 units at $4.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 261,388 units (SEC Form 4)
- SEC Form 4 filed by Van Well Daan
- SEC Form 4 filed by Xu Zhenyu
- SEC Form 4 filed by Valente Manuela
- SEC Form 4 filed by Menu Philippe
- SEC Form 4 filed by Camblong Jurgi
- SEC Form 4 filed by Muken Ross
- SEC Form 4 filed by Puylaert Kevin
- SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026
- SEC Form 144 filed by SOPHiA GENETICS SA